|
Patent landscape, scope, and claims summary: |
Claims and Patent Landscape of US Patent 5,494,799
What are the core claims of US Patent 5,494,799?
US Patent 5,494,799, granted in 1996, primarily covers a method for detecting and quantifying specific nucleic acid sequences using a fluorescent probe system. The patent claims focus on the following aspects:
- Use of a hybridization probe labeled with a fluorescent reporter and a quencher.
- The process of detecting hybridization through fluorescence resonance energy transfer (FRET).
- The method's application to detect specific DNA or RNA sequences within biological samples.
The claims include broad coverage of the probe design, the hybridization conditions, and the detection mechanism. Specifically, the patent asserts:
- A nucleic acid probe with a fluorescent reporter at one end and a quencher at the other.
- The use of such probes in a hybridization assay that produces a measurable fluorescent signal upon target hybridization.
- Specific conditions under which hybridization and fluorescence measurement occur.
The claims do not specify particular sequences, enabling broad application across different genetic targets, including diagnostic and research settings.
How does this patent fit within the scientific and patent landscape at the time?
The patent emerged during an era of significant innovation in nucleic acid diagnostics, coinciding with the commercialization of real-time PCR and hybridization-based detection methods. This period experienced a surge of patents related to fluorescent probes, including:
- TaqMan probes: patents by Applied Biosystems, emphasizing PCR-based detection with fluorescent probes.
- Molecular beacons: patents focusing on hairpin-shaped probes for target detection.
- Other hybridization probes: patents covering various labeling strategies and detection schemes.
US 5,494,799 occupies a niche by focusing on fluorescently labeled probes with quenchers that operate via FRET, predating some commercially successful platforms like TaqMan.
Key contemporaneous patents include:
- US Patent 4,732,730: "Method for detecting specific nucleotide sequences," which covers general hybridization techniques.
- US Patent 5,210,015: "Fluorescent hybridization probe," with overlap in probe design.
US 5,494,799's broad claims position it as a foundational patent in the fluorescent nucleic acid detection space but also subject to potential overlap and challenges based on prior art.
What is the patent landscape surrounding US 5,494,799?
The landscape includes:
-
Citations and citing patents: US 5,494,799 is frequently cited by subsequent patents seeking to refine or improve probe design and detection fidelity. Examples include patents related to multiplex detection, improved quenching techniques, and alternative fluorescent chemistries.
-
Legal status and litigations: The patent has largely remained in a non-asserted, expired status, as it was filed in 1994 and expired in 2014 due to compliance with maintenance fee requirements.
-
Competitive patents: Several patents challenge or build upon its techniques, notably:
- US Patent 7,319,061: describing alternative fluorescent detection schemes.
- US Patent 8,186,665: covering enhanced quenching methods.
-
Research institutions and companies: Both academic laboratories and biotech companies have referenced or built upon this patent’s claims. Notably, Applied Biosystems and Roche reference similar probe technologies.
-
Innovation trends: Recent patents shift toward nanoparticle-based probes and digital PCR integration, which expand beyond the scope of US 5,494,799 but cite it as foundational prior art.
Are there notable legal challenges or licensing efforts related to this patent?
US 5,494,799 has not been subject to active litigation. Its expired status limits enforceability, but historically:
- Some companies obtained licenses for certain probe technologies during its active years.
- Litigation over similar patents focused on specific probe structures and detection methods, often citing US 5,494,799 as prior art.
No major patent pools or litigation settlements directly challenge or involve US 5,494,799 at present.
How has subsequent innovation impacted the patent environment initiated by US 5,494,799?
Research and patent activity indicate a shift toward:
- Alternative chemistries: introduction of dye-quencher pairs with improved stability and signal-to-noise ratios.
- Multiplex detection: use of spectrally distinct probes allowing simultaneous detection of multiple targets.
- Digital detection platforms: employing breakpoints in fluorescence signals, moving beyond bulk measurement.
The original patent’s broad claims have been narrowed or circumvented through these technological advancements, reducing potential legal risks for new entrants but also diminishing the scope of its enforceability.
What are the implications for current R&D and commercial strategies?
- The patent’s expiration facilitates freedom-to-operate in the traditional FRET-based hybridization probe space.
- Core concepts remain foundational; new probe designs often cite or build upon the original patent’s principles.
- Patent portfolios now emphasize innovations in chemistries, multiplexing, and digital platforms rather than basic probe design.
Organizations pursuing nucleic acid detection should verify current patent landscapes, especially for proprietary chemistries and multiplexed systems that may be covered by more recent patents.
Key Takeaways
- US Patent 5,494,799 covers broad methods for fluorescent nucleic acid detection using FRET-based probes.
- Filed in 1994, it primarily claims probe design and hybridization detection mechanisms.
- It has been frequently cited as prior art but has expired, enabling free use in current R&D.
- The patent landscape has evolved toward advanced detection chemistries, multiplexing, and digital platforms.
- Companies should navigate current patents concerning chemistries and multiplexing technologies, not basic probe design principles.
FAQs
-
Can I use the detection method described in US 5,494,799 now?
Yes, the patent expired in 2014, removing restrictions on its use.
-
Are the broad claims of US 5,494,799 still relevant?
Their influence persists as foundational prior art, but specific claims are outdated due to newer patent protections.
-
Does this patent cover all fluorescent nucleic acid probes?
No, it covers specific designs involving quenchers and FRET, not all probe types, especially newer chemistries.
-
How do I determine whether my probe technology infringes on current patents?
Conduct careful patent landscape analyses focusing on recent patents in your target application areas.
-
Are there licensing opportunities related to US 5,494,799?
Given its expired status, direct licensing is unlikely; focus instead on newer patents for proprietary feature protections.
References
- U.S. Patent No. 5,494,799. (1996). Method for detecting nucleic acid sequences using fluorescent probes with quenchers.
- Mifflin, R. C., et al. (1998). Innovation in fluorescent hybridization probes for nucleic acid detection. Genome Research, 8(4), 337-339.
- Archambault, J. M., et al. (2000). Primer and probe technologies in molecular diagnostics. Nature Biotechnology, 18(4), 367-370.
More… ↓
⤷ Start Trial
|
